BACKGROUND: Transfusion-related acute lung injury (TRALI) is a major complication of hemotherapy that may occur after the transfusion of any blood type component. Several clinical reports have suggested the presence of anti-HLA antibodies in the blood product. This study sought to examine the role of anti-HLA-A2 antibodies in polymorphonuclear neutrophil (PMN) activation and thus in endothelial permeability.
STUDY DESIGN AND METHODS: PMN activation
was assessed by both nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) activity and reactive oxygen species (ROS) production. A coculture assay of EA.hy926 endothelial cells with PMNs or differentiated-PLB-985 cells, a model of neutrophil-like cells, was performed to estimate the impact of ROS on endothelial permeability.
RESULTS: Anti-HLA-A2 antibodies significantly increased PMN activation, with subsequent endothelial dysfunction. Phagocyte NADPH oxidase (NOX2) activity was shown to be involved in this process and ROS themselves were demonstrated to induce VE-cadherin cleavage and endothelial permeability.
CONCLUSION:
Our data may support the existence of a critical anti-HLA-A2 antibody threshold for PMN activation, with NOX2 activity and subsequent endothelial permeability in the two-hit model of TRALI.
T ransfusion-related acute lung injury (TRALI) is a syndrome characterized by respiratory distress after blood transfusion. [1] [2] [3] A clinical definition of TRALI was established in 2004, based on acute respiratory distress, bilateral noncardiogenic pulmonary edema occurring within 6 hours of blood product administration, and hypoxemia. 1, 4 Currently, no biologic diagnostic tests are available. The pathogenesis of TRALI remains unclear, although the risk of TRALI was shown to be increased in transfusion recipients with critical disorders such as sepsis 5 and in patients undergoing cardiac surgery. 6 Anti-human leukocyte antigen (HLA) or antihuman neutrophil antigen (HNA) antibodies in TRALI patients have been found in large proportions in donor blood products, [7] [8] [9] [10] [11] [12] which suggests that such antibodies play a significant role in TRALI. In particular, antibodies targeting HLA-A2, a common HLA antigen in Caucasians, were found in transfusion products, associated with fatal cases of TRALI. 8, 9 Despite the apparent association between anti-HLA antibodies and TRALI, several blood products containing anti-HLA antibodies do not cause TRALI reactions, thus rendering it difficult to predict the risk of TRALI solely on the presence of anti-HLA antibodies in transfusion products. Irrespective of the transfusion procedure, pulmonary polymorphonuclear neutrophil (PMN) activation is a critical component in TRALI patients and has also been observed in animal models. [13] [14] [15] [16] A two-hit model for TRALI has been proposed, 17 with the first hit corresponding to a recipient's predisposition to PMN adhesion on pulmonary endothelium and the second hit relating to the transfusion product, with mediators provoking PMN and endothelial cell activation. However, some TRALI cases did not match with this model, especially in fairly healthy patients. A threshold model has therefore been proposed, 18 in which a PMN activation threshold and endothelium crossing may trigger TRALI. This model has not yet been supported by clear experimental evidence.
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To gain a deeper insight into the TRALI pathogenesis and thereby prevent its occurrence and recurrence, we sought to characterize HLA antibody involvement in PMN activation by using HLA-A2 as an experimental model, with the aim to decipher the impact of activated PMN on endothelial permeability. Anti-HLA-A2 antibodies significantly increased PMN activation, with an associated increase in endothelial dysfunction. Phagocyte NADPH oxidase (NOX2) activity was shown to be involved in this process and reactive oxygen species (ROS) themselves were, for the first time, demonstrated to induce VEcadherin cleavage and endothelial permeability.
MATERIALS AND METHODS

Materials
The chemical reagents used in this study were the following: N-formyl-Met-Leu-Phe (fMLP), phorbol 12-myristate 13-acetate (PMA), horseradish peroxidase (HRP), dimethylformamide (DMF), and bovine serum albumin-fluorescein isothiocyanate conjugate (BSA-FITC; Sigma Aldrich); ECL Western blotting detection reagents (GE Healthcare); protein A columns (Pierce ThermoScientific); monoclonal antibody (MoAb) directed against VEcadherin (clone BV9, Santa Cruz Biotechnology, Inc.); and a Transwell chamber insert (6.5 mm diameter, 8 mm pore, Corning Costar).
Anti-HLA antibodies
HLA Class I-positive antisera were selected from multiparous women who provided informed consent. Detection of anti-HLA Class I and Class II antibodies in sera was performed by flow cytometry (Lifecodes Screening, Immucor) using Luminex microbeads coated with HLA antigen, according to the manufacturer's instructions. Sera positive for anti-HLA Class I antibodies were further characterized for HLA specificities by using both the complementdependent lymphocytotoxicity 20 and Luminex singleantigen assay (Lifecodes Single Antigen, Immucor), the latter being analyzed using computer software (Match it, Immucor). Sera displaying exclusive anti-HLA-A2 specificity (HLA-A2 serum) were used in this study. Pooled AB sera from healthy male donors with negative screening tests were employed as a negative control (HLA(-) serum).
Immunoglobulin G purification from serum
Total immunoglobulins G (IgG) from pooled AB serum (HLA(-) IgG) and HLA-A2 serum (HLA-A2 IgG) were purified using protein A columns (Pierce Protein A columns, ThermoScientific). IgG concentration was measured in purified fraction by the Bradford assay using BSA as protein standard. 21 
Cell culture
The human myeloid leukemia PLB-985 cell line, 22 days. The differentiation medium was changed after 3 days in culture. 24 The human vascular endothelial cell line (EA.hy926) established by the fusion of human umbilical vein endothelial cells and the human lung adenocarcinoma epithelial cell line A549 were a gift from Y. Renaudineau (Brest, France). EA.hy926 was grown in DMEM supplemented with 2 mmol/L L-glutamine, 1% penicillin/streptomycin, and 10% (vol/vol) FBS, as previously described. 25 Using a cell line enabled us to overcome the difficulty of obtaining large numbers of noncontaminated primary cells and to circumvent the requirement of growth factors needed by primary endothelial cells.
Neutrophil isolation
Neutrophil HLA allelic typing was performed on genomic DNA from volunteer platelet donors using the Luminex method with a SSO kit, according to the manufacturer's instruction (LABType, One Lambda). 26 Human PMNs were purified from heparinized blood of HLA-A2 donors (HLA-A2 PMNs) and from those who did not express HLA-A2 (HLA non-A2 PMN), diluted twice in phosphatebuffered saline (PBS) containing 1% (wt/vol) trisodium citrate, using a 33% (vol/vol) Hypaque-Ficoll gradient.
After a 20-minute centrifugation at 800 3 g and 208C, the pellet was subjected to hypotonic lysis for 5 to 15 minutes on ice. After an 8-minute centrifugation at 400 3 g and 48C, the PMN pellet was collected and washed once in PBS. 21 PMNs were counted and then used within the next few hours. Cell viability was superior to 90%, as determined by the trypan blue exclusion method.
Neutrophil priming
For priming experiments, PMNs (4 3 10 6 cells/mL) were incubated at 378C with 50 nmol/L fMLP for 15 minutes or 100 ng/mL lipopolysaccharide (LPS) for 1 hour. In some experiments, 10 nmol/L fMLP or 15 ng/mL LPS was used.
NADPH oxidase activity
PMNs or differentiated PLB-985 cells (2 3 10 5 cells in 50 mL of PBS) were suspended in 200 mL of reaction medium (PBS containing 0.9 mmol/L CaCl 2 , 0.5 mmol/L MgCl 2 , 20 mmol/L glucose, 20 mmol/L luminol, and 10 U/ mL HRP). NADPH oxidase activity was measured by luminol-enhanced chemiluminescence assays performed in a 96-well plate. Photon emission was recorded at 378C for 30 minutes with a microplate luminometer (Luminoskan, Labsystem). 21 PMNs were stimulated by addition in the reaction medium of increasing concentrations of HLA(-) or HLA-A2 IgG, as described in individual results, or 130 nmol/L PMA (final concentration), and ROS production was immediately measured. For the xanthinexanthine oxidase assay, ROS production was measured as previously described in a medium containing luminol and HRP, along with 1 mmol/L xanthine and 0.05 IU/L xanthine oxidase. Chemiluminescence was quantified as relative light units using a kinetic assay with readings every 30 seconds, for 45 to 120 minutes.
Transendothelial permeability assay BSA-FITC fluorescence assay EA.Hy926 cell line was grown until confluence on Transwell chamber inserts of 6.5 mm diameter and 8 mm pore (Corning Costar). The endothelial monolayer culture in the upper compartment was exposed to PBS, resting PMNs (3 3 10 6 cells), PMA-stimulated PMNs (3 3 10 6 cells stimulated with 130 nmol/L PMA), or bradykinin (BK). BSA-FITC was simultaneously added to the upper compartment of each Transwell unit. After various incubation times, endothelial monolayer permeability was measured by BSA-FITC flux across intact monolayers to the lower compartment using fluorometry. Two separate Transwell units were used for each incubation time. 
VE-cadherin shedding
Protein electrophoresis and immunoblotting
Equal volumes of each sample were submitted to 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 27 For Western blotting, proteins were electrotransferred to nitrocellulose membrane at 60 mA for 2.5 hours. Nitrocellulose was incubated for 1 hour in 0.05% (wt/vol) TBS-Tween solution (190 mmol/L NaCl, 25 mmol/L TrisHCl, pH 8.0) containing 2% (wt/vol) lowfat milk proteins and then incubated for 2 hours with the anti-VE-cadherin mouse MoAb (BV9; dilution 1:200). The readout was performed using sheep anti-mouse IgG antibody conjugated with peroxidase (dilution 1:5000) for 1 hour, along with ECL reagents. Immunoblots were compared by densitometry.
Statistical analysis
Data are presented as mean 6 standard deviation (SD). When representative data were obtained, the experiments were repeated at least three times yielding similar results. Results for paired data were compared using the t test. The results that significantly differed (p < 0.05) from the control have been indicated.
RESULTS
Anti-HLA-A2 antibodies activate NADPH oxidase in primed PMNs expressing HLA-A2 antigen
Neutrophils and anti-HLA antibodies have been suggested to play a role in TRALI pathogenesis, yet without any clear evidence for such an implication. We consequently analyzed both the impact of anti-HLA antibodies on neutrophil stimulation and its consequence on endothelial permeability. In the first experiment set, resting PMNs from donors who expressed either HLA-A2 antigen (HLA-A2 PMNs) or HLA-non A2 antigen (HLA non-A2 PMN) were purified and incubated with increasing concentrations of HLA-A2 IgG or HLA(-) total IgG. PMN activation was assessed by the NADPH oxidase activity measured by chemiluminescence. NADPH oxidase activity appeared at concentrations of IgG higher than 100 mg/mL (Fig. 1) . A significant difference of response was observed between HLA non-A2 PMNs and HLA-A2 PMNs in the presence of HLA(-) IgG; however, the activity was low (Fig. 1A) . There was particularly no significant difference between cells treated with HLA(-) IgG and HLA-A2 IgG (Fig. 1B vs. Fig.  1A ). In the TRALI two-hit model, a first hit led to PMN priming. In the next experiment set, PMNs were primed before incubation with anti-HLA-A2 IgG. Two different priming agents, fMLP and LPS, were used. Two concentrations of fMLP and LPS, described as priming concentrations, were first used to confirm that PMNs were not activated in these conditions. NADPH oxidase was measured by chemiluminescence on PMNs submitted to 10 and 50 nmol/L fMLP or to 15 and 100 ng/mL LPS. In fMLP-primed PMNs and LPS-primed PMNs, no significant NADPH oxidase activity was measured whatever the priming agent concentration used (10 or 50 nmol/L fMLP or 15 or 100 ng/ml LPS), compared to untreated conditions ( Fig. 2A) . For further experiments, 50 nmol/L fMLP or 100 ng/mL LPS was used to prime PMNs before IgG treatment. Furthermore, fMLP-primed PMNs or LPS-primed PMNs were submitted to increasing concentration of HLA-A2 IgG or HLA(-) IgG, and NADPH oxidase activity was monitored by chemiluminescence (Figs. 2B and 2C) . A strong increase in NADPH oxidase activity was observed when HLA-A2 PMNs were treated with the highest concentration of HLA-A2 IgG (200 mg/mL), in both priming conditions ( 
Activated PMNs are involved in endothelial permeability induction
The physiologic impact of neutrophil activation on endothelial permeability was next investigated in a coculture assay using endothelial cells and PMNs. Endothelial cells were grown to 80% to 100% confluence on a microporous membrane in a Transwell coculture system (Fig. 3) . The culture medium in the upper compartment was replaced by PBS buffer containing a fixed concentration of BSA-FITC, a tracer molecule, and supplemented with either resting or PMA-stimulated PMNs or not (negative control). BK, an inducer of endothelial permeability, was used as positive control. The permeability was followed by the increasing concentration of the fluorescent marker in the lower compartment (Fig.  3A) . Kinetics clearly showed that after a 30-minute contact period of activated PMNs with endothelial cells, the fluorescent marker in the lower compartment increased similarly to that observed with the positive control (Fig.  3B) . Conversely, the permeability measured in the presence of resting PMNs remained close to that observed in control conditions. After a 60-minute incubation, endothelial permeability significantly increased over time in the presence of PMA-activated PMNs (Fig. 3B,  inset) . These results indicated that PMA-activated PMNs were able to induce endothelial permeability. 
PMNs activated by HLA-A2 IgG specifically induce VE-cadherin shedding
To determine whether PMNs upon anti-HLA-A2 antibody activation could induce endothelial permeability, endothelial cells were then cocultured with primed neutrophils activated by either HLA-A2 or HLA(-) IgG at a high concentration (200 mg/mL). VE-cadherin shedding was used as a permeability marker. VE-cadherin is an adhesion receptor expressed at endothelial cell-cell interactions and involved in endothelium tight junction. 28 The VE-cadherin ectodomain as well as its intracellular domain are critical for the control of endothelial permeability. Endothelial permeability was shown to correlate with proteolytic degradation of VE-cadherin, with an increased concentration of soluble VE-cadherin ectodomain. 29 Coculture supernatant was harvested after a 3-hour contact period of IgG-activated PMNs with endothelial cells. After centrifugation, the supernatant was submitted to Western blotting for the released soluble VE-cadherin ectodomain (Fig. 4A) . We observed, after normalization, a significant increase in the immunoreactive band, with an apparent molecular weight of more than 70 kDa in the event of endothelial cells with PMN stimulated by HLA-A2 IgG, although not with HLA(-) IgG (Fig. 4B) . The extent of permeability upon HLA-A2 IgG stimulation was in the same range of that observed with the BK-positive control. These results indicate that primed PMNs expressing HLA-A2 antigen and stimulated with a critical concentration of HLA-A2 IgG mediate endothelial permeability.
The phagocyte NADPH oxidase is involved in increased endothelial permeability
To evaluate the potential involvement of NADPH oxidase activity in this process, coculture experiments were designed by substituting human PMNs with PLB985 cells differentiated from DMF in neutrophil-like cells. Two types of PLB985 cells were employed: PLB985 cells expressing a functional phagocyte NADPH oxidase after differentiation (WT-PLB985 cells) and Nox2-deficient PLB985 cells (Nox2 -/--PLB985 cells). PMA, a strong activator of neutrophil NADPH oxidase, was used to stimulate PLB985 cells before coculture with endothelial cells. A control experiment was performed with PMA-stimulated PMN. Soluble VE-cadherin ectodomain was measured by Western blotting in the culture medium after a 3-hour incubation period. It was significantly increased in the medium after incubation with both PMA-stimulated PMNs and PMA-stimulated WT-PLB985 cells, compared to the basal level of soluble VE-cadherin fragment in condition of endothelial cells alone (Fig. 5A, WT, and PMN vs. PBS condition). In contrast, the soluble VE-cadherin ectodomain level did not show any significant increase in the presence of PMA-stimulated Nox2 -/--PLB985 cells (Fig.  5A ). These data strongly support the argument of phagocyte NADPH oxidase involvement in endothelial permeability induction.
A B
ROS induce endothelial permeability
We then further characterized the metabolic pathway of the endothelial permeability process upon neutrophil activation while evaluating a possible direct role of phagocyte NADPH oxidase-derived ROS in this process. Confluent endothelial cells were treated for 3 hours with a superoxide anion-generating acellular system (xanthine/xanthine oxidase). A series of preliminary experiments was conducted to determine the xanthine/xanthine oxidase concentration required to generate ROS levels close to those provided by activated PMNs. ROS production by systems containing 1 mmol/L xanthine and varying xanthine oxidase concentrations (0.02 to 0.1 mU/mL) was measured by chemiluminescence. The system containing 1 mmol/L xanthine and 0.05 mU/mL xanthine oxidase produced similar ROS amounts to those of activated PMN (Fig. 5B,  inset) . Endothelial cells were subsequently incubated for 3 hours with xanthine/xanthine oxidase system, and the level of VE-cadherin shedding in the culture medium was analyzed by Western blotting. Results revealed that in presence of ROS-generating acellular system, the signal of soluble VE-cadherin fragment was higher than that measured in buffer or in the presence of Nox2 -/--PLB985 cells (Fig.  5B) . Moreover, endothelial cell treatment with the ROSgenerating acellular system was shown to develop VEcadherin shedding in the same range as that observed with WT-PLB985 cells. These data strongly suggest a direct role of ROS in endothelial permeability induction.
DISCUSSION
The etiology of TRALI has been extensively discussed over the past years. Several models have been proposed, and the popular "two-hit model" has been developed, with first a predisposition of the patient and second the transfusion delivering the trigger. Activation of patient pulmonary PMNs has been shown to be a key event in TRALI. It was previously revealed that anti-HNA antibodies, when binding to their antigen, were able to activate PMN and induce ROS production. 16 Additionally, the involvement of donor HLA antibodies, which are present in the transfused blood product, on PMN activation, is generally accepted. The precise role of anti-HLA antibodies in the TRALI process, however, has not yet been clarified. In this article, we have analyzed both the role of human anti-HLA-A2 antibodies, a common antigen in Caucasians, in human PMN activation, and the consequence on both endothelial dysfunction and vascular permeability. The data herein demonstrated for the first time that HLA-A2 IgG, above a critical threshold concentration, were able to significantly activate PMNs expressing HLA-A2 antigen, resulting in a production of Nox2-derived ROS. The presence of HLA-A2 antigen on neutrophil membrane is necessary for that purpose. It is essential to note that this activation was independent of complement, as it occurred in a plasmafree environment. Moreover, this activation was only observed on primed PMNs, confirming that the patient's predisposition is a critical condition of the TRALI process. Recent data by Silliman and colleagues 30 have shown that anti-HLA-A2 antibodies were able to prime the fMLPactivated NADPH oxidase of PMN from HLA-A2 homozygous donors but not from HLA-A2 heterozygous donors.
In contrast, activation of primed PMN by HLA-A2 IgG was not correlated to the neutrophil expression level of HLA-A2 antigen, as results obtained with primed PMN from HLA-A2 homozygous or heterozygous donors were not significantly different (Fig. S1 , available as supporting information in the online version of this paper). This (1 mmol/L)/xanthine oxidase (0.05 mIU) system (X/XO) was used to produce superoxide anions in an acellular system. Superoxide anion production was measured for 2 hours at 378C by chemiluminescence assay in presence of luminol and compared to NADPH oxidase activity measured in differentiated PLB985 WT or Nox2 -/-stimulated by PMA. Histograms show results of one representative experiment from three independent experiments. *p < 0.05 compared with the condition "PBS alone."
phosphorylation of VE-cadherin and catenins, with the disassembly of the VE-cadherin/catenin complex and subsequent breakdown of the endothelial junctions. 31 We herein established that neutrophil Nox2-derived ROS were directly involved in VE-cadherin shedding, thus in endothelial permeability. We suggested a HLA-A2 IgG-mediated TRALI model combining both the two-hit model and the threshold model (Fig. 6) . The "first hit" corresponds to the patient susceptibility characterized by the presence of primed PMNs and their sequestration in the lung capillary. The "second hit" is attributed to HLA-A2 IgG contained in the blood products that recognize the HLA-A2 antigen present on patient's cells, especially on patient's PMNs. When the concentration of HLA-A2 antibodies is above a threshold, the resulting immune complexes (formed by HLA-A2 antigen and HLA-A2 IgG) induce PMN activation. Activated PMN release Nox2-derived ROS. A direct consequence is the endothelial wall damage, vascular leakage, and pulmonary edema. This model can support the fact that not all patients transfused with a blood product containing HLA-A2 IgG develop a TRALI. At present, this adverse effect is underdiagnosed. One of the preventive measures for reducing TRALI risk is to eliminate all blood products containing HLA antibodies.
This radical procedure leads to further increases in blood donation shortage. Investigating the precise threshold concentration of HLA antibodies with activation properties and the molecular process leading to activation of PMN expressing the corresponding HLA antigen will contribute to the development of less drastic preventive measures for reducing TRALI incidence.
